FDA Again Says PTC Therapeutics Duchenne Drug Is Unworthy of Approval

Sep 26, 2017

According to the U.S. Food and Drug Administration, PTC Therapeutics has failed to supply persuasive evidence that its experimental Duchenne muscular dystrophy drug, ataluren, is effective.

PTC have spent the last year in an effort to bring the drug to market. The FDA has already refused to review ataluren twice because the drug failed to show effectiveness in clinical trials.

Read the Reuters report here

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments